Portfolio Management

By Christie Shilling, Research Analyst We have a running joke among the researchers at Cutting Edge Information.  Many of the key findings from our research can be boiled down to one phrase: Start Early.  Our usual advice for pharmaceutical companies...

One of our recent studies showed that most pharmaceutical and biotechnology new product planning teams play at least some role in their companies’ business development activities.  While most of the companies’ new product planning units contributed to business...

No longer can companies wait until Phase 3, or even Phase 2, to begin commercializing their developing brands.  Today, the pharma industry sees increasingly competitive markets and payers who require more convincing before reimbursing products.  Companies must...

Before prospective pharma products are even knee-deep into development, new product planning teams are tasked to start thinking about their commercialization. Tightening payer budgets and shifting reimbursement requirements are forcing teams to emphasize the value...

To combat the era of patent cliffs, pharmaceutical companies have long been planning strategies to extend the lives of their blockbuster drugs.  Some companies look to preserve their spot in the market by introducing new indications and new formulations.  Others...

The recent news that bapineuzumab, a treatment for Alzheimer’s disease, failed to meet two primary endpoints in a recent Phase III study isn’t great for development partners Pfizer and Johnson & Johnson. The new results show the drug fails to produce clinical...

June marked the annual meeting of the American Society of Clinical Oncology (ASCO). This conference offers the largest window into the next several years of cutting-edge cancer treatments. Trial results are often scheduled for release during this time, and companies...

With patents expiring right and left, pharmaceutical companies are looking for every possible tool to slow revenue losses. Counter-generic strategies are one method to maintain market share, however temporary. Even a period of six months when no generic versions...

By Eric Bolesh, Director of Research In collaborations among pharmaceutical and biotech companies, conflicts inevitably arise — and they can spring from a host of different factors. Here are several of the most common issues that we hear about in...

By Jeremy Spivey,Senior Research Analyst After years of nurturing its global blockbuster and trying to prepare for patent expiration, Pfizer's Lipitor is finally open to direct generic competition in the United States. Ranbaxy, which has 180 days of...